[
    [
        {
            "time": "2019-10-01",
            "original_text": "家药企三季度业绩出炉，3家药企营收超500亿，8家业绩亏损丨2019三季度盘点 亏损",
            "features": {
                "keywords": [
                    "药企",
                    "三季度",
                    "业绩",
                    "营收",
                    "亏损"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "家药企三季度业绩出炉，3家药企营收超500亿，8家业绩亏损丨2019三季度盘点 亏损",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "2019-11-15",
            "original_text": "中国抗体上市首日开盘破发 云南白药5000万美元加持能否点亮商业化之路 连续下跌",
            "features": {
                "keywords": [
                    "中国抗体",
                    "上市",
                    "开盘破发",
                    "云南白药",
                    "加持",
                    "商业化",
                    "连续下跌"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "中国抗体上市首日开盘破发 云南白药5000万美元加持能否点亮商业化之路 连续下跌",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-01-10",
            "original_text": "华创证券2020年度策略观点精粹",
            "features": {
                "keywords": [
                    "华创证券",
                    "年度策略",
                    "观点精粹"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "证券"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华创证券2020年度策略观点精粹",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        }
    ]
]